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ABSTRACT 
Chronic pain is one of the most devastating symptoms reported by rheumatoid arthritis (RA) 
patients. Current treatment strategies are focusing on dampening the inflammatory and 
immunological aspects of RA, but unfortunately subgroups of patients continue to suffer 
from pain, even when the disease is adequately controlled. In this thesis, the work is focused 
on investigating mechanisms underlying arthritis-induced pain using the collagen antibody-
induced arthritis mouse (CAIA) model.  
In Paper I, we describe 50 peptides that are only expressed, and 38 peptides that are 
predominantly expressed in the dorsal spinal cord using liquid chromatography mass 
spectrometry. Intrathecal injection of [des-Ser1]-cerebellin (desCER), one of the peptides 
predominantly expressed in the spinal dorsal horn, induces a dose-dependent mechanical 
hypersensitivity but has no effect on thermal sensitivity in mice. We also show that the 
precursor of desCER is expressed in excitatory interneurons of laminae II/III. This study 
suggests that desCER is a novel pain modulator, and provides a platform for continued 
exploration of novel neuropeptides involved in nociception. 
In Paper II, we report that mice subjected to CAIA display transient inflammation and 
persistent mechanical hypersensitivity. We find an anti-nociceptive effect of a COX inhibitor, 
but only in the inflammatory phase of the CAIA model, and a time-dependent spinal glial 
activation. 
 In Paper III, we report neurochemical changes in dorsal root ganglia (DRGs) and spinal cord 
after induction of CAIA. In the CAIA DRGs, galanin, voltage-gated calcium channel subunit 
α2δ1 and the nerve injury markers ATF3 and GAP43 are up-regulated. Taken together, based 
on the pharmacological and neurochemical profile, our work suggests that antibody-driven 
joint inflammation lead to a partial neuropathic pain phenotype. 
Finally, in Paper IV we focus on the role of lysophosphatidic acid (LPA) in arthritis-induced 
pain. The LPA synthesizing enzyme autotaxin is increased in DRGs from mice subjected to 
CAIA. Systemic treatment with a monoclonal antibody (Ab) against LPA completely 
reverses arthritis-induced mechanical and thermal pain-like behavior and also blocks the up-
regulation of α2δ1 in peripheral sensory neurons of CAIA mice. We also find that the 
expression of α2δ1 remains at basal levels in Lpa receptor-1 (Lpar1) deficient CAIA mice. 
These results provide new insights into the role of the LPA1/α2δ1 axis in arthritis-induced 
pain, suggesting new potential therapeutic targets for pain relief in RA. 
In summary, we have described a battery of pain-related factors involved in CAIA-induced 
hypersensitivity. These results lead to a deeper understanding of pain mechanisms in RA and 
hopefully to new therapeutic approaches to treat the pain component in RA patients. 
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1 INTRODUCTION 
Chronic pain is a prevalent and challenging problem affecting approximately 10-20 % of the 
population globally, resulting in marked reduced quality of life for the individual (Apkarian 
et al., 2009). Pain is also a substantial socio-economical problem due to costs of medication, 
loss of productivity and disability (Andersson et al., 2013). According to a survey in 15 
European countries up to 40% of the patients with persistent pain reported having joint pain 
(Breivik et al., 2006). Osteoarthritis (OA), followed by rheumatoid arthritis (RA), is the most 
common cause of joint pain (Breivik et al., 2006, Lluch et al., 2014). Rheumatoid arthritis is 
an autoimmune and destructive joint disease occurring in around 0.5-1% of the population. It 
is important to note that despite improved disease control, many of the RA patients still suffer 
from persistent joint pain (Smolen and Steiner, 2003, McInnes and Schett, 2011). Drug 
development in the area of chronic pain has so far not been successful, and there are in fact 
currently only few available effective treatments for chronic pain conditions in general 
(Davila and Ranganathan, 2011, Walsh and McWilliams, 2014). Hence, it is critical to 
advance our understanding underlying chronic pain, in order to identify new targets for pain 
relief. 
1.1 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is a chronic, systemic autoimmune disease that affects multiple joints 
(Smolen and Steiner, 2003). The predominant symptoms are pain, stiffness, and swelling of 
peripheral joints. The principal pathophysiological feature of the disease includes inflamed 
synovia with a pronounced infiltration of inflammatory leucocytes, angiogenesis, cellular 
hyperplasia, and changes in the expression of cell-surface adhesion molecules, proteinases, 
and many cytokines. The presence of an inflammatory erosive synovitis (pannus) ultimately 
leads to destruction of cartilage, bone and soft tissues, resulting in long-term deformity and 
loss of joint function (Scott et al., 2010, Lillegraven et al., 2012). Another prominent reason 
for loss of joint mobility is chronic or episodic joint pain, which leads to psychological 
distress and impaired quality of life (Schaible et al., 2009). Rheumatoid arthritis is 
characterized by presence of various autoantibodies in serum and synovial fluid, for example 
antibodies against IgG and IgM (rheumatoid factor), anti-collagen type II antibodies (CII) and 
anti-citrullinated protein antibodies (ACPA) (Song and Kang, 2010, Willemze et al., 2012).  
The main objectives of RA treatment are to decrease joint inflammation, maintain joint 
function, protect articular structures, control systemic involvement and relieve pain (Smolen 
and Aletaha, 2015). The identification of disease-modifying anti-rheumatic drugs (DMARDs) 
and biopharmaceuticals, in particular tumor necrosis factor (TNF) inhibitors, has led to great 
improvements in the treatment outcomes of RA. However, despite improved prognosis pain 
still is a big problem for the RA patients (Smolen and Steiner, 2003, Walsh and McWilliams, 
2014). In fact, many patients continue to suffer from pain even though the disease is under 
good control (Lee et al., 2011, Taylor et al., 2011). 
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1.2 THE COLLAGEN ANTIBODY-INDUCED ARTHRITIS MODEL 
Experimental animal models of arthritis are widely used to study disease pathways and to 
identify novel drug targets and therapeutic approaches (McNamee et al., 2015). In order to 
study chronic inflammatory pain in arthritis, selecting a relevant animal model is extremely 
important. Several models used in studies of arthritis-like pain involve intra-articular injection 
of agents such as Complete Freund’s adjuvant (CFA) and carrageenan, which produce a 
pronounced inflammatory reaction and nociceptive behavior (Pearson, 1956, Sluka and 
Westlund, 1993, Inglis et al., 2005). These models are useful in studies of local short-lasting 
inflammation and the impact of such inflammation on the nervous system. However, they are 
not commonly used in the rheumatology field, as they do not reflect the main clinical picture, 
the chronicity and the pathology of human RA.  
We are using an experimental arthritis mouse model, the CAIA model, in which arthritis is 
induced by an intravenous (i.v.) injection of CII antibody cocktails on day 0, and followed by 
an intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) on day 5, in order to 
synchronize the onset of inflammation and enhance severity and incidence of the disease 
(Nandakumar et al., 2003, Khachigian, 2006, Bas et al., 2012). One advantage, as compared 
to conventional inflammatory pain models, is that arthritis is induced with CII antibodies that 
are also found in serum from RA patients. This is a major strength from a translational 
research point of view. Collagen-induced arthritis (CIA) is the most commonly used RA 
animal model (Brand et al., 2007). Both CAIA and CIA mice have similarities with the 
pathogenesis of RA, and these models are characterized by joint swelling and redness in the 
front and hind paws, and occasionally also knee and vertebral joints are affected. Compared 
to CIA, CAIA has a more rapid and synchronized onset of joint inflammation. The CAIA 
model is commonly utilized in the RA field for disease mechanistic studies, but has so far not 
been employed to explore the pain aspects. Development of clinical signs of arthritis (paw 
and joint swelling and redness) is associated with a robust and highly reproducible behavioral 
hypersensitivity. Strikingly, while the inflammation resolves after 2-3 weeks, mechanical 
hypersensitivity outlasts the inflammation and remains pronounced until the termination of 
the experiment. Hence, it appears that the pain process in the CAIA model can be divided 
into inflammatory and post inflammatory phases. Thus, the CAIA model has the potential to 
provide new insights into how persistent inflammation in the joint affects pain-sensing 
neurons and pain processing in the peripheral as well as the central nervous system (CNS).  
1.3 ARTHRITIS-INDUCED PAIN 
Primary sensory neurons represent the interface between, on one hand, external stimuli at the 
peripheral sensory nerve endings in the skin, alternatively intrinsic organs, and on the other 
hand, the spinal cord and further to supraspinal levels (Melzack and Wall, 1965, Willis, 
2007). To detect and transfer a particular nociceptive or non-noxious stimulus that impinges 
upon the body to the CNS, these sensory neurons have highly specialized adaptations that 
include a battery of neuropeptides, ion channels and receptors. They are also characterized by 
highly ordered patterns of innervations in peripheral targets and central circuits (Woolf and 
Ma, 2007). In the joint, the ligaments, fibrous capsule, meniscus, periosteum and synovial 
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layer are innervated by Aβ-, Aδ- and C-fibers. Noxious (pain) sensation can be evoked from 
these structures as shown in Figure 1 (Schaible et al., 2009, Yang et al., 2013). A different 
nomenclature, group I-IV fibers, can be used for afferent fibers from the joint. Group III and 
IV fibers are very similar to Aδ- and C- fibers, respectively. All primary afferent fibers are 
glutamatergic and many contain one or more neuropeptides, including substance P, calcitonin 
gene-related peptide (CGRP), somatostatin, and galanin. 
 
 
Figure 1. Pain pathways in RA. In the joint, many structures are innervated by pain fibers like Aδ- (green) and 
C-fibers (blue), also called nociceptive fibers. Their cell bodies are located in the dorsal root ganglia (DRGs). In 
RA, painful sensation can be evoked from the peripheral sites and then continuing to the spinal dorsal horn, 
where the primary afferents (peripheral sensitization) couple to interneurons or second order projection neurons 
(central sensitization), sending information towards the brain and giving rise to the sensation of pain (modified 
from Paper III). 
During the development of RA, inflammation and other changes lead to sensitization of the 
primary afferent nociceptive neurons innervating the joint (Schaible, 2014, Walsh and 
McWilliams, 2014). This is mediated locally in the arthritic joint by release of various pro-
inflammatory mediators such as TNF, interleukins (ILs), bradykinin, adenosine triphosphate 
(ATP), as well as neuropeptides. Increased input from such sensitized afferents can lead to an 
augmented release of glutamate and neuropeptides like CGRP and substance P on to spinal 
dorsal horn from central terminals. Together with the activation of microglia and astrocytes in 
the spinal dorsal horn, central sensitization will be induced as indicated in Figure 1.  
1.3.1 Inflammatory and neuropathic pain 
Traditionally, the pain experience is classified as three different types of pain according to 
initiation, causes and underlying mechanisms: acute pain, inflammatory (tissue injury) and 
neuropathic (nerve injury) pain (Scholz and Woolf, 2002). Obviously, the causes of 
inflammatory and neuropathic pain are different. Even though these two types of pain share 
certain mechanisms, expression patterns of pain-related factors like neuropeptides, ion 
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channels and nerve injury markers vary (Xu and Yaksh, 2011). Moreover, with regard to 
treatment there are several options. Inflammatory pain can often be attenuated by 
cyclooxygenase (COX) inhibitors (like diclofenac and ibuprofen) and opioids (like 
buprenorphine) and, further, pain improves as the inflammation resolves. In contrast, 
neuropathic pain is unresponsive to COX inhibitors and requires higher doses of opioids and 
may persist even after the healing of injury. Interestingly, clinical cases of inflammation-
induced chronic pain exhibit both neuropathic and inflammatory components. For instance, in 
RA patients, inflammation and pain are not always parallel, in fact even not related to each 
other (van Laar et al., 2012). This is confirmed by the recent study showing that RA patients 
with well-controlled disease still have neuropathic pain symptoms (Koop et al., 2015).  
1.3.2 Neuropeptides 
Endogenous neuropeptides participate in intercellular signaling and thus can act as 
neurotransmitters or neuromodulators in the nervous system. They are involved in a variety 
of functions such as anxiety, depression, memory, sleep, inflammation and pain (Kilduff and 
Peyron, 2000, Taiwo and Taylor, 2002, Hokfelt et al., 2003). Neuropeptides comprise a 
diverse group of chemically distinct molecules, synthesized in, and released from, a range of 
sensory neurons, and involved in nociceptive signal transduction in different categories of 
experimental pain models (e.g. acute, neuropathic and inflammatory). Mounting evidence 
suggests that expression levels of certain neuropeptides in primary sensory neurons are 
altered in different directions in response to experimental manipulations. For example, after 
nerve injury the excitatory peptides substance P and CGRP are down-regulated, while a 
dramatic up-regulation of neuropeptide Y (NPY) and galanin is found in injured DRGs 
compared to their low basic expression (Hokfelt et al., 1984, Wakisaka et al., 1992, Nothias 
et al., 1993, Zhang et al., 1995, Solway et al., 2011, Zhang et al., 2011). In contrast, 
inflammatory pain, induced in CFA and carrageenan models, is associated with an increase of 
substance P and CGRP levels and release (Smith et al., 1991, Donnerer et al., 1993, Hanesch 
et al., 1993, Galeazza et al., 1995, Calza et al., 1998). However, no expression of NPY in 
DRGs was found in DRGs after tissue inflammation (Ji et al., 1994b). Although up-regulation 
of galanin in peripheral sensory neurons is induced after nerve injury (Hokfelt et al., 1987, 
Coronel et al., 2008), an increase of galanin expression has also been found in DRGs of CFA 
rats (Calza et al., 1998, Calza et al., 2000).  
1.3.3 Ion channels 
Neuronal excitability is regulated by ion channel activity. Open probability and expression 
levels of several ion channels located at the peripheral terminals of nociceptors are altered 
after injury, resulting in increased pain signaling (McCleskey and Gold, 1999, Waxman et al., 
1999). In fact, voltage-gated Ca2+ and Na+ channels and ATP-gated P2X receptors are some 
of these ion channels implicated in the pathogenesis of arthritis-induced pain (Dube et al., 
2009, Eid and Cortright, 2009, Micale et al., 2009, Burnstock et al., 2011). 
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1.3.3.1 Calcium channels  
Voltage-gated calcium channels (VGCCs) are necessary for many critical functions like 
transmitter release and hormone secretion in the body. They are composed of five 
components including α1, α2, β, δ and γ subunits (Zamponi et al., 2015), which provide a 
battery of sites for selective pharmacological modification. According to their 
electrophysiological and pharmacological properties, calcium channels have been divided 
into low-threshold (T-types) and high-threshold (L-, N-, P/Q- and R-types) (Bourinet et al., 
2016). Current therapeutic targets against VGCCs include L-type Cav1.2 calcium channels 
involved in hypertension treatment, T-type Cav3 channels involved in epilepsy, and auxiliary 
subunit α2δ1 for neuropathic pain (Zamponi et al., 2015). The auxiliary subunit α2δ1 
expression is markedly up-regulated in DRG neurons and spinal dorsal horn after peripheral 
nerve injury (Luo et al., 2001, Newton et al., 2001, Li et al., 2006); and it is shown that the 
level of α2δ1 is also modestly elevated in cutaneous DRG neurons after subcutaneous 
injection of CFA (Lu et al., 2010). Moreover, α2δ1 is thought to be the target of the drugs 
gabapentin and pregabalin, which are widely used for treatment of, among others, 
neuropathic pain (Li et al., 2006). By binding to α2δ1 they block Ca2+-flux into the cell and 
thereby attenuate hypersensitivity in both neuropathic and inflammatory pain models 
(Maneuf et al., 2006, Sills, 2006). Loss of function studies with α2δ1 knockout mice show 
dramatically reduced injury-induced hypersensitivity to mechanical and cold stimuli, which 
confirms that α2δ1 is a key component of the nociceptive pathways (Patel et al., 2013). 
1.3.3.2 Sodium channels 
Voltage-gated sodium channels play fundamental roles in the excitability of neurons, by 
initiating and propagating action potentials along axons (Mantegazza and Catterall, 2012). 
The distinct sodium channel subtypes like Nav1.3, Nav1.7, Nav1.8 and Nav1.9 are expressed 
on peripheral sensory neurons and have been implicated in persistent pain (Liu and Wood, 
2011, Dib-Hajj et al., 2013). Nav1.3 is normally absent in the naïve DRGs, but dramatically 
up-regulated after sciatic nerve injury (Lindia et al., 2005). Nav1.7 expression is increased in 
DRGs neurons after peripheral inflammation, like CFA and formalin inflammation models, 
and blockage of Nav1.7 in nociceptors attenuates pain hypersensitivity in several 
inflammatory pain models (Gould et al., 2004, Nassar et al., 2004). But Nav1.7 has not yet 
been associated with neuropathic pain (Nassar et al., 2005). In contrast, increased expression 
of Nav1.8 is found in DRGs followed by both inflammation and nerve injury (Amir et al., 
2006). Blocking Nav1.8 abolishes inflammatory pain (Yu et al., 2011), but only attenuates 
some types of neuropathic pain (Stirling et al., 2005, Kistner et al., 2010). Moreover, Nav1.9 
is selectively expressed in small-sized DRG neurons (Fukuoka et al., 2008), and the 
expression level is significantly elevated after CFA injection (Tate et al., 1998) but reduced 
followed nerve injury (Berta et al., 2008). These findings suggest that sodium channels are 
differentially regulated in inflammatory and/or neuropathic pain conditions. 
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1.3.3.3 ATP-gated ion channel P2X3 
Besides voltage-gated ion channels, ligand gated ion channels, including purinergic 
ionotropic receptors like P2X receptors activated by ATP, are considered to play significant 
roles in nociceptive signal transduction, as shown in different experimental pain models 
(Hamilton et al., 2001, Tsuzuki et al., 2001, Xu and Huang, 2002, Averill et al., 2004, Tsuda 
et al., 2010). A specific ATP-sensitive ligand-gated ion channel, the P2X3 receptor has 
generated considerable interest in view of its role in the initiation of nociceptive signaling 
(Xiang et al., 2008, Fukuoka et al., 2012). P2X3 is significantly increased in DRGs after 
nerve injury (Novakovic et al., 1999, Wang et al., 2010), and blockage of P2X3 by treatment 
with an antagonist can attenuate nerve injury-induced pain-like behavior (Hansen et al., 
2012). However, a decrease in P2X3 receptor protein expression in primary sensory neurons 
has been shown after CFA inflammation, which is also significantly related to pain-like 
behavior in experimental rats (Xu and Huang, 2002).  
1.3.4 Nerve injury markers 
Activating transcription factor 3 (ATF3), a member of the ATF/CREB family of transcription 
factors originally identified in a variety of stressed tissues, is induced in DRG neurons upon 
nerve injury (Chen et al., 1996, Tsujino et al., 2000). ATF3, normally not or only very rarely 
expressed, is induced in DRG neurons as early as 12 hr, peaks after 3 days and decreases after 
6 weeks of axotomy (Tsujino et al., 2000). Growth-associated protein 43 (GAP43), identical 
to growth associated protein B-50, is up-regulated in response to nerve lesion and involved in 
peripheral nerve regeneration (Jacobson et al., 1986, Van der Zee et al., 1989). Although 
ATF3 has also recently been shown to contribute to nerve regeneration by orchestrating gene 
expression responses in peripheral injured neurons (Seijffers et al., 2006, Seijffers et al., 
2007, Chandran et al., 2016), it is still, together with GAP43, a useful nerve injury marker. 
The hypothesis that prolonged joint inflammation may have “nerve damaging” impact on 
sensory neurons has been examined using these factors. Interestingly, expression of ATF3 is 
elevated in DRGs in the late phase of the K/BxN-serum transfer arthritis (Christianson et al., 
2010) and the CIA (Inglis et al., 2007), but not in the AIA model (Segond von Banchet et al., 
2009). These markers appear to be specific to certain states of nerve injury-induced pain, as 
there is no increased expression of ATF3 or GAP43 in primary neurons following 
inflammation by CFA and carrageenan injection.  
1.3.5 Glia activation 
In the past two decades great progress has been made demonstrating that non-neuronal cells, 
that is glia, play crucial roles in the pathogenesis of pain, especially in the chronic pain state. 
Spinal glial activation has been observed in experimental studies on pain, including 
inflammatory, neuropathic and cancer pain models (Sweitzer et al., 2001, Zhang et al., 2003, 
Ji et al., 2013). Usually, glial activation displays morphological changes such as hypertrophy 
or process retraction/extension, including up-regulation of the glial markers such as ionized 
calcium-binding adapter molecule 1 (Iba1) in microglia, and glial fibrillary acidic protein 
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(GFAP) in astrocytes (Meller et al., 1994, Vale et al., 2004).  
Historically glia has been considered to provide physical and nutritional support for the 
neuronal network. However, since the early 1990’ies increasing evidence suggests that glia 
plays a variety of roles in spinal sensitization. After painful stimulation or injuries (tissue 
or/and nerve), both microglia and astrocytes show morphological and functional signs of 
activation, including: i) increased activity in intracellular pathways, like the mitogen-
activated protein kinases (MAPKs) pathways, as indicated by e.g. increased phosphorylation 
of p38 in microglia, and c-Jun N-terminal kinase (pJNK) in astrocytes and ii) production and 
release of glia mediators such as pro-inflammatory cytokines and growth factors; and these 
factors are thought to act on spinal neurons and contribute to spinal sensitization (McMahon 
and Malcangio, 2009). In addition, glia inhibitors can attenuate the initiation and reverse the 
maintenance stages of chronic pain (Watkins and Maier, 2003). It is an intriguing thought that 
difficulties in developing new pain therapeutics may in part be due to an overseen role of glia. 
Hence, it is critical to explore the role of these cells in pain transmission and to determine the 
feasibility of targeting astrocytes and/or microglia in conditions of chronic pain. 
1.3.6 Lysophosphatidic acid 
The bioactive glycerophospholipid lysophosphatidic acid (LPA) is an important signaling 
molecule, present in numerous tissues and fluids, notably within the developing and adult 
nervous system (Yung et al., 2015). While 18-carbon long unsaturated (C18:1) LPA is the 
most studied form (Figure 2), many other chemical forms of LPA with different acyl chain 
lengths, saturation, and position also exist (Yung et al., 2014). LPA is generated through 
several different enzymatic pathways with two major ones being actions of autotaxin (ATX) 
and phospholipases such as phospholipase A2 enzymes (PLA2). These pathways generate 
both intracellular and extracellular LPA (Pages et al., 2001).  Extracellular LPA initiates 
various intracellular signaling cascades by binding and activating at least six 7-
transmembrane G-protein coupled receptors denoted LPA1-LPA6 (Noguchi et al., 2009, 
Yung et al., 2014) (mouse gene and mRNA for these receptors are referred to as Lpar1-
Lpar6) and therefore involved in both physiological and pathophysiological processes. 
Accumulating data point to an important role of LPA and corresponding receptors in pain 
signaling. First, both i.p. and intrathecal (i.th.) injection of LPA (18:1) induce mechanical and 
thermal hypersensitivity in the paws lasting for at least 30 min and 7 days, respectively 
(Renback et al., 1999, Inoue et al., 2004), indicating that LPA is involved both in peripheral 
and spinal mechanisms of nociceptive signal transmission. Second, the use of transgenic mice 
and pharmacological tools demonstrates that several LPA receptors contribute to the 
development and/or maintenance of neuropathic, inflammatory and bone cancer pain (Inoue 
et al., 2004, Sevastou et al., 2013, Ueda et al., 2013). For instance, genetic removal of Lpar1, 
Lpar3 or Lpar5 prevents nerve injury-induced pain like behavior (Inoue et al., 2004, Lin et 
al., 2012, Ueda et al., 2013), and in addition, LPA3 and LPA5 have been implicated in 
nociceptive signal transmission in the spinal cord after nerve injury (Ma et al., 2009, Lin et 
al., 2012). Of note, both mechanical and thermal hypersensitivity induced by i.th. injection of 
LPA are abolished in either Lpar1 or Lpar3 deficient mice (Ma et al., 2010, Kashimoto et al., 
2013).  
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Figure 2. LPA synthesis by the enzyme autotaxin from LPC (modified from Paper IV). 
LPA and LPA receptors have gained attention as they have the potential to be crucial factors 
in multiple mechanisms leading to chronic pain, including the induction of peripheral 
sensitization, structural reorganization, demyelination and spinal glia activation. In 
experimental models of neuropathic pain, LPA1 activation has been coupled to up-regulation 
of the calcium ion channel subunit α2δ1 in DRG neurons and up-regulation of protein kinase 
C gamma (PKCγ) in the spinal dorsal horn (Inoue et al., 2004), contrasting LPA5 activation 
to the modulation of cAMP response element binding protein (CREB) in the spinal cord (Lin 
et al., 2012). Furthermore, increased expression of LPA3 has been observed in activated 
microglia after nerve injury (Ma et al., 2009), which is thought to serve as a positive feedback 
for amplifying LPA synthesis (Ma et al., 2013). This notion is supported by the observation 
that i.th. injection of LPA increases LPA production, suggesting that LPA itself plays 
important roles in the amplification of LPA biosynthesis. Interestingly, LPA-induced 
enhancement of LPA synthesis was abolished in Lpar3-deficient mice (Ma et al., 2013). 
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2 AIMS OF THESIS 
The overall aim of this thesis is to explore, at the cellular and molecular level, mechanisms 
underlying pain processing at the lumbar spinal level in the CAIA mouse model of RA. These 
mechanisms are associated both with neurons and non-neuronal cells, that is glia. They 
encompass DRG neurons with peripheral branches in the skin and central projections in the 
dorsal horn, where the local interneurons and projection neurons participate. The thesis has 
three specific aims: 
1. To identify peptides only expressed in the dorsal region of the mouse spinal cord 
using liquid chromatography mass spectrometry (LCMS). And, further, to analyse, as 
proof-of-concept, one identified, novel peptide with regard to involvement in pain 
processing.  
 
2. To identify and quantify a number of molecules, including neuropeptides, channels 
and receptors in the mouse DRGs and spinal cord after collagen antibody 
administration with special focus on comparison between the two phases of the 
arthritis: the inflammatory phase and the chronic phase.  
 
3. To investigate the role of LPA in arthritis-induced hypersensitivity, especially in the 
chronic phase. 
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3 MATERIALS AND METHODS  
3.1 ANIMAL MODEL 
3.1.1 Induction of CAIA 
CBA male mice (Scanbur, Stockholm, Sweden) were kept in the animal facility at the 
Department of Physiology and Pharmacology, Karolinska Institutet according to established 
procedures. Arthritis was induced by i.v. injection of 150 mg 5 monoclonal collagen type II 
antibodies cocktail on day 0 (Chondrex, Redmond, WA), boosted with i.p. injection of 30 µg 
LPS on day 5 (Chondrex). After antibody injection, the inflammation started from day 6, 
reached a peak on day 15 and resolved by day 33. In contrast, the control mice injected either 
only with saline or with LPS did not show any signs of inflammation. 
3.1.2 Pain-like behavior assessment 
3.1.2.1 Mechanical hypersensitivity (von Frey test) 
For mechanical measurement the mice were habituated to the test environment on two 
occasions before assessment of baseline. After three baseline recordings performed on 
different days, the animals were randomly assigned to control (saline and LPS) and CAIA 
groups. Mechanical sensitivity was determined by assessment of paw withdrawal using von 
Frey optiHair filament (Marstock OptiHair, Schriessheim, Germany) with the up-down 
method as previously describe (Chaplan et al., 1994). A series of filaments with a 
logarithmically incremental stiffness of 0.5, 1, 2, 4, 8, 16 and 32 mN (converted to 0.051, 
0.102, 0.204, 0.408, 0.815, 1.63, 3.26 gram, respectively) was used and the top of the 
filament was applied to the plantar surface of the hind paw and held for 2-3 s. In order to 
avoid tissue damage a cut off of 4g was applied. A brisk withdrawal of the paw was noted as 
a positive response. The 50% probability withdrawal threshold (force of the von Frey hair to 
which an animal reacts to 50% of the presentations) was calculated (Chaplan et al., 1994).  
3.1.2.2 Heat hypersensitivity 
To assess heat sensitivity, a Hargreaves-type testing device (UARDG, Department of 
Anesthesiology, University of California, San Diego, 92103-0818) was used as previously 
described (Dirig et al., 1997, Svensson et al., 2005). Briefly, mice were placed in plexiglas 
cubicles on a glass surface maintained at 25 °C. The thermal nociceptive stimulus originates 
from a projection bulb below the glass surface, and the stimulus is delivered separately to one 
hind paw at a time. A timer was activated by the light source and automatically turned off by 
a motion sensor. Latency was defined as the time required for the paw to show a brisk 
withdrawal. Each hind paw was tested three times and the average withdrawal latency 
calculated. 
3.1.2.3 Cold hypersensitivity 
Cold hypersensitivity was measured by the acetone test. Acetone (one drop) was applied to 
the hind paw without touching the skin and the response of the mouse to acetone was 
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observed for 60 s and graded on a four-point scale, as modified from Flatters and Bennett 
(Flatters and Bennett, 2004). Based on the time spent expressing nocifensive behavior, the 
following scores were determined: 0 for no response, 1 for total reaction time less than 1 s, 2 
for total reaction time between 1 and 3 s, 3 for total reaction time between 3 and 10 s, 4 for 
total reaction time longer than 10 s as previously described (Su et al., 2014). The test was 
repeated three times, and data from two hind paws were presented as median with 
interquartile range. 
3.2 PRIMARY NEURON CULTURE 
Around 30 DRGs were dissected (different levels of spinal ganglia) from adult CBA male 
mice and placed in 6 cm petri-dish with DPBS (Sigma, St. Louis, MO) on ice. The ganglia 
were digested in a 37 °C incubator with 3 ml papain (Sigma) for 30 min and followed by 1.5 
ml collagenase and 1.5 ml dispases (Sigma) treatments. After digestion, ganglia were 
transferred to a 15 ml focal centrifuge tube with 6 ml of L15 medium containing 10% fetal 
bovine serum (FBS, Fisher Scientific, Waltham, MA) and 100 units/ml penicillin-
streptomycin (Sigma). Ganglia were triturated with 1 ml pipette (Fisher Scientific) until the 
suspension was homogeneous. Single cell suspensions were filtered through a cell-strainer 
(100 µm, BD Biosciences, Stockholm, Sweden) and then incubated in 6 cm dishes to allow 
non-neuronal cells especially glia cells (satellite cells) to attach. After 90 min, the supernatant 
was collected and the cells (mixture of neurons and glia cells) were seeded 200 µl/well into 
48-well plate pre-coated with L-type polylysine and laminin (Sigma). 
3.3 MASS SPECTROMETRY 
3.3.1 Sample preparation 
Mice were deeply anesthetized with isoflurane and decapitated. Dissected spinal cord 
samples were immediately heat stabilized with the Stabilizor system (Skold et al., 2007). 
After stabilization, the spinal dorsal and ventral parts from cervical and lumbar enlargements 
were separated under a dissecting microscope. Peptides were extracted using Peptide 
extraction Kit (Denator AB, Uppsala, Sweden) according to the manufacturer’s instructions 
with modifications (Svensson et al., 2003). 
3.3.2 Peptide quantification and identification 
Peptide separation was performed using a nano-flow liquid chromatography (LC) system and 
then directly electrosprayed into the mass spectrometer, a hybrid linear ion trap (LTQ) 
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer equipped with a 7T 
ICR magnet. The mass-to-charge ratio of ions and their levels were recorded in the 
instrument. The acquired data was quantified using the software DeCyder MS2.0 (GE 
Healthcare, Uppsala, Sweden). Peptide identities were established using the software X! 
Tandem (Craig and Beavis, 2004) and MASCOT Daemon (version 2.3, Matrix Science, 
London, UK) to search the resulting data against an in-house made compilation of mouse 
precursors containing known neuropeptides and peptide hormones.  
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3.4 IMMUNOHISTOCHEMISTRY 
3.4.1 Sample preparation 
Mice were deeply anesthetized with sodium pentobarbital (60mg/kg) and transcardially 
perfused with 20 ml pre-warmed (37 °C) saline, followed by 20 ml pre-warmed 4% 
paraformaldehyde containing 0.2% picric acid in 0.16 M phosphate buffer (pH 7.2-7.4) and 
50 ml cold fixative (Su et al., 2015). Lumbar 4 and 5 DRGs were dissected and post-fixed in 
the same fixative for 90 min at 4 °C. After cryoprotection with 10% sucrose in 0.1 M 
phosphate buffer containing 0.01% sodium azide (VWR International, Spanga, Sweden) and 
0.02% bacitracin (Sigma) for 48 hr, DRGs were embedded with OCT (HistoLab, Vastra 
Frolunda, Sweden), frozen with liquid carbon dioxide and sectioned on a CryoStar NX70 
cryostat (Thermo Scientific, Walldorf, Germany) at 12 µm thickness.  
3.4.2 Normal method 
For immunocyto-staining, the fixed cells were permeabilized with 0.3% Triton X-100/PBS 
for 10 min, and then non-specific antibody-binding sites were blocked with 5% normal goat 
serum in 0.3% Triton X-100/PBS for 30 min at room temperature (RT) and then incubated 
with rabbit anti-α2δ1 antibody and mouse anti-MAP2 monoclonal antibody. The 
corresponding Alexa-conjugated secondary antibodies (Invitrogen, Carlsbad, CA) and DAPI 
(Invitrogen) were used to visualize the cells. In each coverslip, 12 areas were selected 
randomly, and the α2δ1 positive neurons were counted, and its percentage in the MAP2 
positive cells was calculated.  
3.4.3 TSA plus method 
Mounted sections were dried at RT for at least 30 min and then incubated with primary 
antibodies diluted in phosphate-buffered saline (PBS) containing 0.2% (wt/vol) BSA (Sigma) 
and 0.3% Triton X-100 (Sigma) in a humid chamber at 4 °C overnight. Immunoreactivities 
were visualized using the TSA Plus kit (PerkinElmer, Waltham, MA) as previously described 
(Su et al., 2015). For double labeling, sections of mouse and human ganglion already stained 
with LPA1 by using TSA plus kit were rinsed with PBS and incubated with α2δ1 antibody 
(1:400) in the humid chamber at 4 °C for 48 hr. After washing, the α2δ1 staining was 
visualized with secondary IgG (H+L) antibody conjugated with carbocyanin 3 (Cy3, 1:150, 
Jackson ImmunoResearch Laboratories, West Grove, PA) at RT (22 °C) for 90 min. 
Counterstaining was performed on single labeling sections with 0.001% propidium iodide 
(PI, Sigma) for 10 min at RT. Double labeled sections were counterstained with DAPI 
(Sigma) for 15 min at RT. After rinse in PBS, the sections were mounted with DABCO 
medium. Antibodies used in this thesis are listed in Table 1. 
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Table 1. Primary antibodies used for immunohistochemistry 
 
3.4.4 Image analysis and quantification 
Representative images were captured in an LSM710 confocal laser-scanning microscope 
(Carl Zeiss, Oberkochen, Germany) from one airy unit operated with ZEN2012 software 
(Zeiss). The proportion of neuron profiles (NPs)  (number of immuno-positive NPs / total 
Antigen Description of 
Immunogen Source, Host Species and Cat. 
Concentration or  
Dilution  
α2δ1 
Synthetic peptide 
corresponding to amino 
acids 528-668 of human 
α2δ1 
Sigma, rabbit polyclonal, 
HPA008213 
 
0.05µg/ml (TSA) 
ATF3 
Recombinant protein 
corresponding to amino 
acids 194-212 of Human 
ATF3 (C-terminal) 
Santa Cruz, rabbit polyclonal,  
sc-188 
 
0.05µg/ml (TSA) 
Calbindin 
D-28k 
Recombinant rat calbindin 
D-28k 
Swant, rabbit polyclonal, 
CB-38 
1:4,000 (TSA) 
CBLN1 
KLH-conjugated synthetic 
peptide corresponding to 
amino acids 95-112 of 
mouse CBLN1 
Morgan J.I. (Memphis, TN) 1:10,000 (TSA) 
CGRP 
Synthetic peptide 
corresponding to amino 
acids 23-37 of Tyr-α-r 
CGRP 
Terenius L. (Stockholm, 
Sweden), 
rabbit polyclonal  
1:20,000 (Normal)  
galanin 
Albumin-conjugated, 
synthetic peptide 
corresponding to amino 
acids 1-29 of rat galanin 
Theodorsson E. (Linköping, 
Sweden), 
rabbit polyclonal  
1:4,000 (TSA) 
GAP43 
Recombinant protein 
corresponding to full-
length of rat GAP43 
Chemicon, rabbit polyclonal, 
ab5220,  
 
7.5µg/ml (TSA) 
GFAP GFAP isolated from cow spinal cord 
DAKO, rabbit polyclonal, 
IS524 
1:500 (Normal) 
Iba1 
Synthetic peptide 
corresponding to C-
terminal amino acids of 
Iba1 
WAKO, rabbit polyclonal, 
019-19741 
1:200 (Normal) 
LPA1 
Synthetic peptide 
corresponding to amino 
acids 342-359 of human 
EDG2 
Abcam, rabbit polyclonal, 
Ab23698 
1:1,000 (TSA) 
MAP-2 Bovine brain microtubule protein 
Millipore, mouse monoclonal, 
MAB3418 
1:300 (Normal) 
NPY 
Synthetic peptide 
corresponding to full-
length of porcine NPY 
Wong H. and Walsh JH. (UCLA, 
CA), 
rabbit polyclonal  
1:4,000 (TSA) 
P2X3 
Synthetic peptide 
corresponding to amino 
acids 383-397 of rat P2X3 
Elde R. (Minneapolis, MN),  
rabbit polyclonal  
1:2,000 (TSA) 
substance 
P 
Albumin-conjugated, 
synthetic peptide 
corresponding to full-
length of substance P 
Terenius L. (Stockholm, 
Sweden), 
rabbit polyclonal  
1:2,000 (TSA) 
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number of NPs labeled by propidium iodide) in DRGs was calculated from three or four 
randomly selected sections. 
3.5 QUANTITATIVE REAL-TIME PCR (TAQMAN) 
Animals were deeply anesthetized (5% isoflurane) on day 15 and 45 after arthritis induction, 
and L4 and L5 DRGs were harvested after decapitation by dissection. The tissues were 
immediately flash frozen and stored at -70 ºC until analysis. Total RNA was extracted from 
DRGs using Trizol (Invitrogen) according to the manufacturer’s protocol. Complementary 
DNA was prepared and quantitative real-time PCR (StepOne system) performed using 
hydrolysis probe following the manufacturer’s protocol. Pre-developed validated 
primer/probe sets for Lpar1-6 and as Hprt1 were used for mRNA analysis (Table 2) (TaqMan 
Gene Expression Assays, Applied Biosystems, Foster City, CA). Threshold cycle values in 
each sample were used to calculate the number of cell equivalents in the test samples using 
the standard curve method (Boyle et al., 2003). The data were normalized to Hprt1 mRNA 
levels, and the data expressed as percentage of control values. In some experiments the delta 
Ct method targets normalized to Hprt1 expression was used to obtain relative concentration 
and presented as mean ± SD. 
Table 2. Primers used for real-time qPCR 
Genes Taqman primer 
Atf3 Mm00476033_m1 
Cacna2d1 Mm00486607_m1 
Enpp2 (Atx) Mm00516572_m1 
Galanin Mm00439056_m1 
Gap43 Mm00500404_m1 
Hprt1 Mm01318743_m1 
Lpar1 Mm01346925_m1 
Lpar2 Mm00469562_m1 
Lpar3 Mm00469694_m1 
Lpar4 Mm01228532_m1 
Lpar5 Mm01190818_m1 
Lpar6 Mm00613058_s1 
P2rx3 Mm00523699_m1 
Scn9a (Nav1.7) Mm00450762_s1 
Scn10a (Nav1.8) Mm00501467_m1 
 
3.6 IN SITU HYBRIDIZATION 
Antisense and sense RNA probes specific for mouse and human Lpar1 were synthesized 
using sequence specific primers (mouse Lpar1 forward primer 5’-
ATGAGGACACTCCTGTACTTAACA-3’; reverse primer 5’-
GAAAGGCATACTGAATACACACAC-3’, human Lpar1 forward primer 5’-
 16 
CCCCAGTTCACAGCCATGAATGAACC-3’; reverse primer 5’-
CATGCGGAAAACCGTAATGTGCCTCT-3’) and cDNA obtained from mouse brain and 
human hypothalamus. The PCR fragments were subcloned into pCRII-TOPO vector 
(Invitrogen) and transcribed by T7/Sp6 RNA polymerase (Life Technologies, Carlsbad, CA) 
in the presence of 35S-UTP (Perkin Elmer, Boston, MA). Sense probes were used as negative 
controls. 
In situ hybridization was performed as described previously with minor modifications (Le 
Maitre et al., 2013). Briefly, mouse and human DRG sections were post-fixed in 4% 
paraformaldehyde and treated with 0.25% acetic anhydride in 0.1M triethanolamine (pH 8.0). 
The sections were gradually dehydrated in a series of alcohol and stored at -20 °C until use. 
The sections were pre-hybridized with 50% (vol/vol) deionized formamide (pH 5.0), 50 mM 
Tris-HCl (pH 7.6), 25 mM EDTA (pH 8.0), 20 mM NaCl, 0.25 mg/ml, yeast tRNA and 2.5× 
Denhardt’s solution for 4 hr at 55 °C and followed by hybridization with 35S labeled Lpar1 
probe in a humidified chamber at 55 °C for 16- 20 hr. The 35S-labeled Lpar1 probes were 
diluted to a final concentration of 1.0x106 cpm/200 µl in the hybridization solution containing 
50% (vol/vol) deionized formamide (pH 5.0), 0.3 M NaCl, 20 mM DTT, 0.5 mg/ml yeast 
tRNA, 0.1 mg/ml poly-A-RNA, 10% (vol/vol) dextran sulfate, and 1× Denhardt’s solution. 
After hybridization, sections were rinsed as follows: twice for 30 min in 1× SSC at 55 °C, 1 
hr in 50% (vol/vol) formamide/0.5× SSC at 55 °C, 15 min in 1× SSC at 55 °C, 1 hr in RNase 
A buffer at 37 °C, twice for 15 min in 1× SSC at 55 °C, then dehydrated in ascending alcohol 
series (2 min each), and finally were air dried. The sections were exposed to Kodak BioMax 
MR film (VWR International) and then dipped in an autoradiographic emulsion. After a 
determined exposure time (6 weeks for mouse Lpar1 and 8 weeks for human Lpar1), slides 
were developed using D19 developer (Kodak, Rochester, NY) for 3 min and AL4 fixative for 
7 min, dried at room temperature. The sections were dehydrated with graded alcohol, dipped 
in xylene and mounted with Entellan.  
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4 RESULTS AND DISCUSSION 
In this thesis, four projects were performed to study the molecular mechanisms underlying 
RA-induced pain. 
4.1 NEUROPEPTIDES IN THE MOUSE SPINAL CORD AND DESCER AS A 
NOVEL PAIN MODULATOR 
4.1.1 Identification and quantification of peptides in the mouse spinal cord 
Neuropeptides were initially considered as transmitter-like substances and had emerged as the 
largest group of messenger molecules in the nervous system (Burbach, 2010). However, 
neuropeptides might in some cases be difficult to quantify using classical antibody-based 
techniques such as immunohistochemistry, western blotting and radioimmunoassay. We are 
using label-free liquid chromatography high-resolution tandem mass spectrometry (LCMS) to 
identify and semi-quantify neuropeptides, which is based on the amino acid-sequence, to 
explore potential new peptides that might be involved in pain. Using non-organic solvents we 
identified 204 peptides originating from protein precursors in naïve mouse spinal cord. Of 
these, 36 were previously well-characterized full-length neuropeptides, and 168 had not been 
previously characterized. Further, a majority of them had typical neuropeptide cleavage sites, 
thus they might represent potential functional peptides in the nervous system (27 already 
identified and 118 novel peptides). 
From a pain perspective, neuropeptides released from central terminals of peripheral 
nociceptors and interneurons are more likely to play roles in pain transmission, if they are 
expressed in the dorsal horn than the ventral horn of the spinal cord. Totally 137 out of the 
204 peptides were found in both dorsal and ventral parts, from cervical and lumbar spinal 
cord. We found 50 peptides that were only expressed in the dorsal region, while 38 peptides 
were predominantly expressed in the spinal dorsal part (Figure 3A). Some of the peptides that 
were exclusively or predominantly located in the dorsal horn had previously been proven 
important transmitters in nociception. For instance, protachykinin-1-drived peptides 
substance P, neurokinin A and C-terminal-flanking peptide were predominantly expressed in 
the spinal dorsal horn. Both substance P and neurokinin A participate in pain signal 
transmission (Ribeiro-da-Silva and Hokfelt, 2000). Thus, based on both the location and 
precursor protein, C-terminal-flanking peptide is a candidate for further study on pain.  
4.1.2 desCER as a novel modulator in spinal nociception 
In our first step in examining the roles of the novel peptides, we focused on one peptide 
called [des-Ser1]-cerebellin (desCER), originating from cerebellin precursor protein 1 
(CBLN1), which was expressed 6 times more in dorsal region as compared to ventral part. 
The cerebellins (CBLNs) represent a family of secreted proteins, belonging to the C1q/TNF 
super family, which display wide but distinct expression patterns throughout the nervous 
system of many species, from chicken to man. The CBLN family comprises four members, 
CBLN1-4, which have distinct functions in synapses formation, maintenance and plasticity 
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(Joo et al., 2011, Martinelli and Sudhof, 2011, Matsuda and Yuzaki, 2011, Mishina et al., 
2012) and are important during cerebellum development (Rucinski et al., 2009) and for long-
term depression (Yuzaki, 2009). As there were no published studies describing the 
distribution of CBLNs in the nervous system outside the brain of adult mice, or a possible 
relationship to nociception, we decided to investigate the location of the precursor protein and 
the potential functional role of desCER in pain signal transmission in more detail. 
Immunohistochemistry showed expression of CBLN1 with a punctate staining in neuronal 
cytoplasma throughout the spinal gray matter. The immunofluorescence signal was much 
stronger in the dorsal compared to the ventral part, and predominantly present in lamina II 
and lamina III (Figure 3B). CBLN1-immunoreactive (IR) neurons co-localized with 
calbindin, a marker for excitatory interneurons, thus indicating that desCER could be released 
from excitatory neurons. Injection (i.th.) of desCER induced mechanical hypersensitivity in a 
dose-dependent manner, but did not alter the sensitivity to thermal stimuli in naïve mice, 
neither heat nor cold. This study provides evidence for the involvement of desCER in 
nociception through spinal pain circuits and, importantly, provides a platform for continued 
exploration of involvement of novel neuropeptides in the regulation of nociceptive 
transmission.  
 
Figure 3.  Neuropeptides in mouse spinal cord. (A) Using mass spectrometry, 50 neuropeptides were found 
exclusively expressed in dorsal spinal cord of naïve mouse, and 38 neuropeptides were predominantly expressed 
in the dorsal region. (B) Red docs showed the precursor protein CBLN1 expression in mouse spinal cord. 
CBLN1-drived peptide desDER is one of 38 predominantly dorsal expressed peptides found by mass 
spectrometry. CBLN1 expressed throughout the grey matter, predominantly in Laminae IIO/III. Abbreviations: 
LD = lumbar dorsal region; CD = cervical dorsal region; CV = cervical ventral region; LV = lumbar ventral 
region; CBLN1 = cerebellin 1 precursor. (Modified from Paper I) 
4.2 COLLAGEN ANTIBODY–INDUCED ARTHRITIS EVOKES PERSISTENT 
PAIN WITH SPINAL GLIAL INVOLVEMENT  
4.2.1 CAIA induces transient inflammation and persistent hypersensitivity 
We successfully induced CAIA in three different mouse strains: QB, BALB/c and CBA. All 
three stains developed transient inflammation and persistent hypersensitivity after injection of 
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collagen type II antibodies and LPS. Interestingly, even though there was a strain-dependent 
distribution of the inflammation (fore versus hind paw) and time to resolution, they 
developed similar mechanical pain-like behavior, and importantly, in all three strains 
mechanical hypersensitivity persisted for weeks after the visual signs of inflammation 
disappeared. I focused on the CBA strain in this thesis, and induction of CAIA in CBA mice 
led to an increase in arthritis scores 6 days after injection of the collagen antibody cocktail, 
with the disease severity peaking around day 15. The signs of visual inflammation (arthritis) 
were transient, and were no longer detectable by day 36. Interestingly, CBA mice subjected 
to CAIA displayed more severe signs of arthritis in the fore paws compared to the hind paws, 
which was not the case for BALB/c or QB mice, where the distribution of inflammation was 
more even between fore and hind paws. The CBA CAIA mice showed reduced tactile paw 
withdrawal thresholds from day 3, even before arthritis was observed, and lasted till the end 
of the experiment. No signs of inflammation or hypersensitivity were found in saline or LPS 
control groups. We refer to the days with visible inflammation as the “inflammatory phase”, 
and the period that starts 10 days after the visible signs of inflammation has disappeared as 
the “post-inflammatory phase” or late phase. In CBA mice this typically meant that the post-
inflammatory phase started around day 45.    
During the inflammatory phase (day 16), the CAIA mice displayed higher acetone scores 
compared to the saline and LPS groups. However, no differences of acetone score were found 
between CAIA and control groups on day 42, indicating that CAIA induced transient cold 
allodynia only in the inflammatory phase. Moreover, using Hargreaves box for assessment of 
heat sensitivity long-lasting heat hypersensitivity in the CAIA mice was recorded. After 
induction of CAIA, mice showed a significantly decreased latency to heat stimulation 
compared to the control groups, both on day 17 and on day 43. These results showed that 
CAIA evokes transient joint inflammation and cold allodynia but persistent mechanical and 
heat hypersensitivity. In the RA patients, thermal (cold and heat) and pressure sensitivity are 
increased in a variety of anatomical sites, including both inflamed joints and non-inflamed 
tissues (Jahanshahi et al., 1989, Edwards et al., 2009). In this case, the CAIA model displays 
similar pain hypersensitivity as RA patients and could be relevant for studies of underlying 
mechanisms of the disease. 
4.2.2 COX inhibition attenuates CAIA-induced mechanical hypersensitivity 
only in the inflammatory phase 
We assessed the effect of analgesic drugs, such as gabapentin (anticonvulsant used for 
treatment of neuropathic pain), buprenorphine (opioid) and diclofenac (COX inhibitor), on 
mechanical hypersensitivity in the CAIA mice during both phases. During the inflammatory 
phase, all three drugs attenuated the mechanical hypersensitivity 2 and/or 4 hours after drug 
administration. In the postinflammatory phase, gabapentin and buprenorphine increased 
mechanical threshold in the CAIA mice, but no analgesic effect was observed after injection 
of diclofenac. Thus, COX inhibition was anti-nociceptive only during the inflammatory 
phase, indicating a time-dependent prostaglandin dependence in arthritis-induced pain. In 
contrast, gabapentin and buprenorphine attenuated hypersensitivity to mechanical stimulation 
in the CAIA mice in both phases. These results further underline the view that joint 
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inflammation can cause a drift towards mechanisms that partly resemble neuropathic pain in 
the chronic pain state.  
4.2.3 CAIA induces time-dependent glia activation in the spinal cord 
Spinal glia activation has been detected and involved in central sensation following nerve 
injury. In the spinal cord of CAIA mice, signs of increased microglia and astrocyte activity 
were detected by immunohistochemical assessment of Iba-1 and GFAP, respectively. Spinal 
Iba-1-like immunoreactivity (LI) was increased and microglia morphology altered in the 
dorsal horn of mice subjected to CAIA, most prominent during the inflammatory phase but 
still detectable in the late phase. In contrast, an increased immunofluorescence signal of 
spinal GFAP and altered astrocyte morphology were only detectable in the late phase of the 
CAIA model. By western blotting, we found that the levels of phosphorylated JNK in the 
spinal cord were pronouncedly increased in the late phase of arthritis in the CAIA model. In 
addition, i.th. injection of the JNK inhibitor JIP-1 partially reversed mechanical 
hypersensitivity in the late phase, indicating that spinal JNK participated in the modulation of 
arthritis-induced pain transmission. We were, however, not able to demonstrate in which cell 
type JNK phosphorylation was elevated due to technical problems (none of the antibodies 
bought from Promega, Santa Cruz Biotechnology or Cell Signaling Technology worked for 
immunohistochemistry). Others have demonstrated that JNK is activated in spinal astrocytes 
in models of chronic pain, and one may thus speculate that this is the case also in our study. 
However, i.th. injection of the non-specific “glia inhibitor” pentoxifylline reversed CAIA-
induced mechanical hypersensitivity. Thus taken together, these data point to an involvement 
of spinal glia in regulation of spinal nociceptive signal transmission initiated by a RA-like 
joint pathology.  Our finding shows that CAIA represents a multifaceted model for studies 
exploring the mechanisms of pain induced by inflammation in the joint, while a time-
dependent spinal glial activation contributes to antibody-induced pain. 
4.3 PHENOTYPIC CHANGES IN DORSAL ROOT GANGLIA AND SPINAL 
CORD IN THE CAIA MICE 
4.3.1 CAIA alters expression of neuropeptides and ion channels in DRGs  
The focus of this study was to investigate the molecular basis for long-term alterations in 
nociceptive pathways induced by polyarthritis using the CAIA mouse model. In this model, 
mechanical hypersensitivity is persistent even after the joint inflammation is resolved.  We 
have examined expression levels of pain-related markers including neuropeptides, ion 
channels and nerve injury markers in DRGs and spinal cord, both during the peak of visual 
joint inflammation (day 15) and when the hypersensitivity persists without sign of 
inflammation (days 45-47).  
In lumbar DRGs, based on immunohistochemistry staining results with antisera to substance 
P, CGRP, NPY and galanin, the latter was the only neuropeptide that was significantly 
increased in the CAIA group. While the number of galanin-IR NP was increased both 15 and 
47 days after antibody injection, no difference in galanin signal intensity or size distribution 
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was found between CAIA and control groups. In spinal cord, galanin-LI in L4/L5 spinal 
dorsal horn was analyzed but showed similar expression levels in the three groups. Galanin is 
a well-kwon neuropeptide involved in nociceptive signaling transmission (Ji et al., 1994a, Liu 
and Hokfelt, 2002). After nerve injury, there is an increase of galanin in the small sized DRG 
neurons, with a typical shift to expression also in medium-to-large sized neurons (Villar et al., 
1988, Zhang et al., 1998, Zhang et al., 2011). This increase in galanin expression is thought 
to be a part of recruitment of a program associated with neuropathic pain. Of note, while no 
changes in galanin expression in DRGs during peripheral inflammation induced by 
carrageenan (Ji et al., 1995), an increase in galanin expression was found in rat DRGs after 
CFA injection at the base of the tail (Calza et al., 2000). Thus, an increase in the percentage 
of galanin-IR DRG neurons was found in the CAIA mice, which suggests that antibody-
driven joint inflammation may cause injury-like changes in the peripheral sensory neurons, 
or/and that galanin up-regulation can be induced by a certain type(s) of inflammatory 
processes, including arthritis. 
Besides neuropeptides, we also examined, if induction of CAIA alters the expression of ion 
channels such as calcium channels (focused on the α2δ1 subunit) and the ATP-gated ion 
channel P2X3. Pronounced up-regulation of the α2δ1 subunit was found in the CAIA DRGs 
both in terms of the proportion of α2δ1-IR neurons and signal intensity during the 
inflammatory and post-inflammatory phases. Furthermore, size distribution analysis also 
showed that CAIA led to a shift of α2δ1-IR neurons towards left, from large to medium sized 
neurons, which suggests there is a shift from Aβ fibered sensory neurons to Aδ fiber 
nociceptors after CAIA induction. We found that the percentage of P2X3- positive NPs was 
elevated in DRGs both 15 and 47 days after arthritis induction, but no alterations in P2X3 
signal intensity or soma size distribution were observed in the CAIA mice compared to 
control groups. We also wanted to investigate, if CAIA evokes changes in sodium ion 
channels but here, again, we ran into antibody problems. Of the Novus Biologicals and 
Alomone Labs antibodies that were tested for Nav1.7 and Nav1.8 with 
immunohistochemistry, none showed reliable staining. Thus, we turned to quantitative real-
time PCR. We did not observe any changes in mRNA levels of Nav1.7 or Nav1.8 within the 
three groups in either of the two phases. In conclusion, CAIA causes up-regulation of galanin, 
α2δ1 and P2X3 in the DRGs without altering the expression of CGRP, substance P, NPY or 
sodium channels.  
4.3.2 Long-time joint inflammation causes changes in expression of nerve 
injury markers 
In addition to pain-related factors we have also examined, two nerve injury markers in CAIA 
DRGs. While ATF3 was transiently induced (only increased in DRGs on day 15), GAP43 
was up-regulated in DRGs both on day 15 and day 47. Furthermore, to investigate which 
subpopulation of neurons was involved in CAIA DRGs, we did double-staining of GAP43 
with CGRP (peptidergic neuron marker) or isolectin Griffonia simplicifolia I-B4 (IB4, non-
peptidergic neuron marker) (Donnerer et al., 1993, McMahon and Priestley, 1995). We found 
that GAP43 was predominantly co-expressed in CGRP-positive neurons. This indicates that 
damaged neurons mostly belong to the peptidergic subpopulation. Thus, it is possible that 
 22 
arthritis pathology in the joint primarily affects peptidergic nociceptors, and causes stress or 
injury-like changes in the peripheral nervous system. 
Different types of pain are often classified based on the underlying pain generating condition 
as being predominantly inflammatory or neuropathic. Based on the literature (Table 3), 
sciatic nerve transection leads to an increased expression of a variety of neurochemical 
markers in DRGs, including the neuropeptides galanin and NPY, sodium channel Nav1.7, 
and the nerve injury markers ATF3 and GAP43 (Hokfelt et al., 1984, Wakisaka et al., 1992, 
Nothias et al., 1993, Solway et al., 2011, Zhang et al., 2011). In contrast, expression levels of 
these factors are not altered in classical inflammatory pain models such as the formalin and 
carrageenan models (Ji et al., 1994b). On the other hand, CGRP and substance P are down-
regulated after nerve injury but increased in DRGs after peripheral inflammation (Smith et 
al., 1991, Donnerer et al., 1993, Hanesch et al., 1993, Galeazza et al., 1995, Calza et al., 
1998). Furthermore, up-regulation of the α2δ1 subunit in DRGs is detected both after nerve 
injury (Luo et al., 2001, Newton et al., 2001) and inflammation induced by injection of CFA 
to the paw (Lu et al., 2010). In addition, expression of the P2X3 receptor is elevated in the 
DRGs after sciatic nerve lesions (Novakovic et al., 1999, Wang et al., 2010) but is decreased 
in sensory neurons after CFA inflammation (Xu and Huang, 2002). 
Neurochemical markers like galanin, P2X3, ATF3, and GAP43 are modulated in CAIA 
DRGs in a fashion similar to what is observed after nerve injury, but the expression of other 
factors such as NPY, CGRP and substance P are not affected by CAIA-induced joint 
inflammation, even though they are elevated either by nerve injury or other types of 
inflammatory reactions. Therefore, the present results indicate that CAIA-induced changes in 
DRGs has some features in common with neuropathic pain models, and suggest that 
antibody-mediated joint inflammation could “damage” peripheral branches of sensory 
neurons.  
Table 3. CAIA induces a unique plastic phenotype in the DRGs. 
 CAIA Tissue Inflammation Nerve Injury 
substance P − é ê 
CGRP − é ê 
NPY − − é 
galanin é − é 
Nav1.7 − é − 
P2X3 é ê é 
α2δ1 é é é 
ATF3 é − é 
GAP43 é − é 
 ‘é’means up-regualtion, ‘ê’means down-regulation and ‘−’ indicates no change. Tissue inflammation 
(Carrageenan and CFA model) and nerve injury  (sciatic nerve axotomy) data are based on the literature. 
The present results demonstrate that the CAIA model generates a pain state with a unique and 
highly distinct neurochemical signature. Thus, antibody-driven inflammation has a disease-
specific phenotype. Of note, similar “non-typical” changes in the expression of pain-related 
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factors in both the spinal cord and DRGs have been demonstrated in models of bone cancer 
(Honore et al., 2000), indicating that bone cancer pain is distinctly different from classic 
inflammatory or neuropathic conditions and suggesting that cancer pain is a unique type of 
persistent pain. Determining the disease-specific neurochemical changes involved in 
initiating and/or maintaining pain may provide a mechanistic platform for discovering of new 
agents targeting different pain states. 
4.4 BLOCKAGE OF LPA REVERSES CAIA-INDUCED HYPERSENSITIVITY 
AND ALPHA2DELTA1 EXPRESSION IN DRGS 
4.4.1 LPA is elevated in the CAIA DRGs  
LPA can be synthesized by several enzymes, but it is thought that a large proportion of LPA 
is generated by ATX, which is released by activated platelets in the circulation and 
accumulates at the local site of the inflammation or injury (Inoue et al., 2008), including the 
arthritic joint (Barbayianni et al., 2015). Moreover, ATX is necessary for self-amplification 
of LPA production in the spinal cord after nerve injury (Ma et al., 2013), and this feed-
forward of LPA synthesis acts as an important mechanism underlying sustained neuropathic 
pain (Ueda et al., 2013). Locally increased ATX and LPA were detected in arthritic synovium 
in both RA patients and animal models, and genetic ablation of ATX or LPA1 attenuated 
disease pathogenesis in the animal models (Nikitopoulou et al., 2012, Miyabe et al., 2013). 
We are, however, the first to examine the role of LPA in an animal model of arthritis-induced 
pain. We found that Atx mRNA levels were significantly elevated in L4/L5 DRGs 15 days 
after collagen antibody injection, but that there was no difference in Atx mRNA levels in 
DRGs between CAIA and the control groups in the late phase (day 45). In naïve adult mice, 
Lpar1, Lpar5 and Lpar6 mRNA were abundant in DRGs, while Lpar2, Lpar3 and Lpar4 
were relatively sparsely expressed. Moreover, when we examined if the gene expression of 
Lpars was altered in response to induction of CAIA, we did not detect any difference in 
mRNA levels for any of the six Lpars in L4/L5 DRGs between the CAIA and control mice, 
neither in the inflammatory nor late phase. Though not studied directly, our data indicate the 
possibility that LPA levels are increased in DRGs through up-regulation of ATX in response 
to CAIA during the inflammatory phase, and contribute to enhancement of arthritis-induced 
pain in the DRGs. It will be important to assess, if ATX activity is increased also in the joint, 
and if LPA acts on LPA receptors expressed on the afferent terminals.  
4.4.2 Systemic blockage of LPA by monoclonal antibody reverses in the 
CAIA-induced hypersensitivity  
To investigate the effect of blocking LPA action on already established arthritis-induced 
pain-like behavior, we injected a murine monoclonal Ab against LPA from day 12 to day 45 
subcutaneously (s.c., twice/week) after injection of CII antibodies. Control antibody without a 
target in the mouse was used as a control in this experiment. The CAIA mice showed a 
transient increase in arthritis score, peaking around day 15. There was no difference in 
severity of joint inflammation between the groups that received LPA Ab, control Ab or saline 
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(Fig. 4A), indicating that LPA did not maintain CAIA-induced inflammation. In contrast, 
while CAIA mice injected with saline or control Ab showed a significant reduction in 
withdrawal threshold from day 3 through day 45, injection of LPA Ab completely reversed 
CAIA-induced mechanical hypersensitivity after three times of s.c. injection (10 mg/kg) (Fig. 
4B). Systemic injection of a lower dose (2 mg/kg) of LPA Ab also attenuated mechanical 
hypersensitivity in the CAIA mice. Thus, LPA Ab blocks CAIA-induced hypersensitivity in a 
does-dependent manner. Moreover, LPA Ab also reversed CAIA-induced mechanical 
hypersensitivity even when the treatment was initiated on day 57. Notably, LPA Ab injection 
completely reversed CAIA-induced heat hypersensitivity in both phases and attenuated cold 
hypersensitivity during the inflammatory phase (Fig. 4C and D). Further, in order to examine 
the effect of LPA Ab treatment on the generation of RA pain, we also injected LPA Ab s.c. 
starting 8 days before the arthritis induction, and continued with twice/weekly administration 
until 15 days after CAIA injection. We found that pretreatment with LPA Ab prevented 
CAIA-induced mechanical hypersensitivity without any visual effect on the inflammation. 
Taken together, blocking LPA’s actions by a neutralizing antibody both prevented and 
reversed CAIA-induced mechanical hypersensitivity, without reducing the joint 
inflammation. Also, LPA Ab treatment attenuated thermal hypersensitivity (both heat and 
cold) in the CAIA mice. Hence, it seems that LPA plays an important role(s) in the initiation 
and maintenance of arthritis-induced hypersensitivity. Of note, even though we did not 
couple LPA to visual signs of joint inflammation, other studies have suggested that LPA 
regulates RA-associated inflammatory responses and apoptosis of fibroblast-like 
synoviocytes (Orosa et al., 2015). Treatment with an ATX inhibitor or LPA receptor 
antagonist attenuates disease severity of experimental arthritis induced by K/BxN and CIA 
(Orosa et al., 2012, Nikitopoulou et al., 2013, Orosa et al., 2014). Thus, though not evident in 
the CAIA model, blocking the ATX/LPA/LPA1 pathway may serve as a therapeutic 
approach not only for pain relief but also for RA pathogenesis.  
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Figure 4. Systemic neutralization of LPA reverses CAIA-induced pain-like behavior. (A) Subcutaneous (s.c.) 
LPA antibody treatment twice per week day 12-45 does not influence arthritis scores at any time point but (B) 
reverses mechanical hypersensitivity, and (C) paw withdrawal latency for heat hypersensitivity both in the 
inflammatory and late phases. (D) Cold hypersensitivity only develops in the inflammatory phase and is 
alleviated by LPA antibody treatment. Mechanical hypersensitivity expressed as mean ± SEM, other data 
expressed as mean ± SD (from Paper IV). 
4.4.3 Blockage of LPA action reverses CAIA-induced α2δ1 up-regulation 
It has previously been reported that LPA1-mediated up-regulation of α2δ1 in the peripheral 
nervous system is prominent in experimental models of neuropathic pain (Inoue et al., 2004). 
In agreement with the study described above, we found that both the percentage and signal 
intensity of α2δ1 expression was increased in the cytoplasm of DRG neurons, especially in 
medium to large-sized neurons on day 47 in CAIA mice compared to saline controls. Of note, 
the up-regulation of α2δ1 in CAIA DRGs was not present in CAIA mice treated with the 
LPA Ab compared to CAIA mice receiving the control mAb. Furthermore, the up-regulation 
of α2δ1 was totally abolished in Lpar1-/- mice injected with CAIA, both in terms of the 
number and fluorescence intensity of α2δ1-IR neurons. Meanwhile, there was no change in 
intensity of LPA1-LI signal in CAIA DRGs by immunohistochemistry, which confirmed lack 
of change in mRNA levels of Lpar1 in the CAIA animal compared to the control group. Up-
reguation of α2δ1 has been observed after nerve injury and i.th. injection of LPA 18:1, and 
usually associates with hypersensitivity. Moreover, blocking of LPA1 by antagonists or using 
transgenic animals can reverse both the α2δ1 expression and pain-like behavior.  It indicates 
that CAIA-induced up-regulation of α2δ1 can be blocked with LPA Ab treatment and 
abolished in Lpar1-/- transgenic mice. 
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To examine the direct effect of LPA on expression of nociceptive factors in the DRG 
neurons, we applied three different species of LPA into DRG primary culture of adult mouse. 
Western blotting data showed that the protein expression of α2δ1 was significantly up-
regulated 4 hours after application of LPA 18:1 (highest affinity for LPA1, 10 µM) but not 
LPA 18:2 (highest affinity for LPA3, 10 µM) or cLPA 18:1 (highest affinity for LPA5, 10 
µM) compared to vehicle. Moreover, α2δ1 gene expression was transiently elevated in the 
cultured DRGs after LPA 18:1 stimulation, peaking at 4 hours. Interestingly, no difference of 
galanin or Gap43 expression was found in the cultured DRG stimulated by LPA 18:1.  
LPA1 expression in mouse DRGs has been reported previously based on qPCR and western 
blotting methodology (Inoue et al., 2004). However, the cellular location of LPA1 in the 
DRGs has not been examined. Therefore we assessed the cellular distribution of LPA1 by 
riboprobe in situ hybridization in both human and mouse DRGs. In mouse DRGs, Lpar1 
mRNA was exclusively expressed in non-neuronal satellites cells. And LPA1 antibody also 
showed staining in satellite cells surrounding the neurons, which was completely abolished in 
the Lpar1 KO DRGs. In human ganglion, Lpar1 mRNA showed a ring-like distribution 
surrounding neurons, which was confirmed at the protein level by the LPA1 antibody. 
Confocal images showed cytoplasmic immunostaining of α2δ1 in neurons and a surrounding 
LPA1-positive satellite cell staining both in the mouse and human DRGs (cover photo). 
Further studies are warranted in order to dissect how LPA1 activation of satellite cells leads 
to increased α2δ1 expression in neurons. Intriguingly, hitherto unexplored communications 
between these two cell types may play an important role in chronic pain. 
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5 CONCLUDING REMARKS 
This thesis focuses on studying molecular mechanisms underlying RA-induced pain with 
special attention to involvement of neuropeptides, ion channels, and spinal glia activation. 
Using LCMS we have identified 50 peptides, which are only expressed in the dorsal region of 
the spinal cord, and 38 peptides that are predominately expressed in this region. One of these 
peptides, desCER, is explored in behavioral experiments and shown to induce a dose-
dependent mechanical hypersensitivity but not heat or cold hypersensitivity. This study 
provides evidence for involvement of desCER in nociception and forms the basis for 
continued exploration of involvement of novel neuropeptides in the regulation of nociceptive 
transmission. Thus, we have a window of opportunity to study novel peptides expressed in 
spinal cord, and we will focus especially on dorsally expressed peptides, as they are more 
likely to be involved in pain processing, compared to ventrally expressed peptides. 
Furthermore, in an ongoing LCMS analysis we are examining how the expression of 
peptides, including desCER, is changing in the spinal cord after induction of CAIA. 
We report that CAIA evokes a transient joint inflammation and cold allodynia but persistent 
mechanical and heat hypersensitivity. We have characterized the CAIA model from the pain 
perspective by using pharmacological and histochemical phenotypic profiling: i) While 
gabapentin and buprenorphine attenuate mechanical hypersensitivity both in the 
inflammatory and post inflammatory phases, the analgesic effect of diclofenac is confined to 
the inflammatory phases. ii) Microglia and astrocytes are activated in the spinal dorsal horn, 
and inhibition of glia activation reverses CAIA-induced mechanical hypersensitivity. iii) 
CAIA causes up-regulation of galanin, α2δ1, ATF3 and GAP43 in the DRG neurons. These 
data indicate that long-term, antibody-driven joint inflammation causes a nerve injury-like 
phenotype, which gives a deeper understanding of the complexity of the mechanisms 
underlying pain in RA. According to our finding, broader therapy strategies might be 
explored for treatment of pain in RA, like glial inhibition, blocking the action of galanin and 
preventing activation of P2X3 (which are up-regulated in the CAIA DRGs). Moreover, since 
CAIA induced a neurochemical phenotype that resembles nerve damage, analgesic drugs 
used for neuropathic pain probably could probably be used for treatment of RA pain, 
particularly in the chronic phase.     
We show that systemic treatment of CAIA with an LPA Ab completely reverses arthritis-
induced mechanical and thermal pain-like behavior. The LPA antibodies also block the up-
regulation of the voltage-gated calcium channel subunit α2δ1 in peripheral sensory neurons, 
which is also abolished in the Lpar1 deficient mouse. Thus, blockage of LPA by applying 
therapeutic antibodies may represent an efficacious approach to treat arthritis-induced pain 
via the LPA1/α2δ1 pathway, that is via a peripheral site of action. In this project, we are using 
murine monoclonal antibody against LPA to neutralize the action of LPA in initiation and 
maintenance of arthritis-induced pain. Further, based on the ATX/LPA/ LPA receptor 
pathway, new drugs could be developed and tested for pain relief in RA patients. For 
instance, ATX inhibitors and several different LPA receptors antagonists show anti-
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nociceptive effect in neuropathic pain models, which raises the possibility to treat RA pain. 
Moreover, compared to animal experiments, very few studies explore human DRGs as we 
have done in the present study. Including human samples seems relevant and offers a 
valuable translational perspective. 
To conclude, I show desCER as a novel modulator in spinal nociception, and that CAIA-
induced hypersensitivity is associated with a time-dependent activation of prostaglandin 
mechanisms and spinal glia activation. In addition, I describe neurochemical changes of 
neuropeptides and ion channels in the CAIA DRGs and spinal cord. Last but not least, I show 
an antinociceptive effect of an LPA Ab in the CAIA mouse with involvement of the 
LPA1/α2δ1 axis. These results may help to understand pain mechanisms in RA diseases, and 
identify molecules involved in arthritis-induced pain, in particular the chronic state. 
Hopefully, my work will help answering some questions related to arthritis-induced pain and 
bring light to potential new targets for pain relief in RA.  
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